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The recent discovery of sensory (tastant and odorant) G protein-
coupled receptors on the smooth muscle of human bronchi sug-
gests unappreciated therapeutic targets in the management of
obstructive lung diseases. Here we have characterized the effects
of a wide range of volatile odorants on the contractile state of
airway smooth muscle (ASM) and uncovered a complex mecha-
nism of odorant-evoked signaling properties that regulate
excitation-contraction (E-C) coupling in human ASM cells. Initial
studies established multiple odorous molecules capable of increas-
ing intracellular calcium ([Ca2+]i) in ASM cells, some of which were
(paradoxically) associated with ASM relaxation. Subsequent stud-
ies showed a terpenoid molecule (nerol)-stimulated OR2W3
caused increases in [Ca2+]i and relaxation of ASM cells. Of note,
OR2W3-evoked [Ca2+]i mobilization and ASM relaxation required
Ca2+ flux through the store-operated calcium entry (SOCE) path-
way and accompanied plasma membrane depolarization. This che-
mosensory odorant receptor response was not mediated by
adenylyl cyclase (AC)/cyclic nucleotide-gated (CNG) channels or
by protein kinase A (PKA) activity. Instead, ASM olfactory re-
sponses to the monoterpene nerol were predominated by the ac-
tivity of Ca2+-activated chloride channels (TMEM16A), including
the cystic fibrosis transmembrane conductance regulator (CFTR)
expressed on endo(sarco)plasmic reticulum. These findings dem-
onstrate compartmentalization of Ca2+ signals dictates the odor-
ant receptor OR2W3-induced ASM relaxation and identify a
previously unrecognized E-C coupling mechanism that could be
exploited in the development of therapeutics to treat obstructive
lung diseases.
olfactory receptor | G proteins | airway smooth muscle | single-cell
analysis | asthma
Asthma, an inflammatory disorder of airways, presents aglobal healthcare challenge with over 300 million individ-
uals now afflicted worldwide (1). The root cause of asthma
morbidity, and in some cases death, is airway hyperresponsiveness
(AHR) or excessive airway narrowing due to airway smooth
muscle (ASM) shortening (2–4). An enhanced shortening of ASM
cells contributes to asthma exacerbations from a variety of stimuli
such as exercise, cold air, allergens, air pollution, and viral
infection (5–8).
β-Agonists are effective bronchodilators, routinely utilized for
the acute treatment of bronchospasm and for the prophylactic
management of asthma symptoms when chronically adminis-
tered. These agents relieve airflow obstruction by activating β2-
adrenergic receptors (β2ARs) that are G protein-coupled re-
ceptors (GPCRs) expressed on the smooth muscle of human
bronchi, inhibiting basal tone and ASM shortening (9, 10). The
regular use of β-agonists, however, can induce drug tolerance or
loss of their clinical efficacy (11). In addition, increased airway
inflammation (12), bronchial hyperreactivity (13, 14), and other
adverse effects, including death (15, 16), have been observed in
various clinical trials of β-agonists. Consequently, there is an
unmet need to identify new therapeutic targets whose activation
or inhibition can directly modulate excitation-contraction (E-C)
coupling and relax ASM.
We have recently reported “sensory” GPCRs of the bitter
taste receptor (TAS2R) family and the olfactory receptor (OR)
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family expressed on human ASM cells (17–19). TAS2Rs reverse
bronchoconstriction by an unclear mechanism that is associated
with Ca2+-activated K+ (BKCa) channels, evoking membrane
hyperpolarization and ASM relaxation (19–22). Human ASM
cells also express multiple ORs and their obligate downstream
effectors, the olfactory G protein (Golf) and adenylyl cyclase III
(AC3) (17). Of note, activation of the odorant receptor OR51E2
via its cognate ligands acetate and propionate results in marked
reductions in cytoskeletal remodeling and ASM proliferation
(17). These physiological outcomes mediated by endogenous
metabolic byproducts of the gut microbiota (i.e., short chain fatty
acids) suggest previously unidentified “ancient” chemosensors of
the gut-lung axis. The findings also give rise to the notion that
ectopic expressions of sensory receptors can be exploited to
discover disease-modifying therapeutics for asthma (23).
Here we tested on ASM the physiological effects of volatile
chemicals occupying a wide odorant space, using optical mag-
netic twisting cytometry (OMTC). After having established both
procontractile and prorelaxant effects of various odorous mole-
cules, subsequent studies focused on the regulatory mechanism
of a terpenoid odorant (nerol) on ASM signaling and shortening
through its reported odorant receptor OR2W3 (24–26). The
monoterpene nerol evoked calcium flux, relaxed isolated human
ASM cells in vitro, and reversed carbachol-induced broncho-
constriction ex vivo in human precision cut lung slices (hPCLSs).
Down-regulation of OR2W3 in human ASM cells by RNA in-
terference led to significant inhibitions of nerol-induced [Ca2+]i
mobilization and ASM relaxation. Surprisingly, OR2W3-
mediated increases in [Ca2+]i and the associated ASM relaxa-
tion were narrowly tuned to the store-operated calcium entry
(SOCE) pathway and accompanied membrane depolarization,
displaying signaling properties distinct from those of the β2AR
and TAS2R. The chemosensory mechanism of the odorant re-
ceptor OR2W3 in ASM did not involve adenylyl cyclase (AC)/
cyclic nucleotide-gated (CNG) channels, but was predominated
by the activity of Ca2+-activated chloride channels belonging to
the anoctamine family of membrane proteins (TMEM16A) and
the cystic fibrosis transmembrane conductance regulator
(CFTR) expressed on endo(sarco)plasmic reticulum (ER).
These findings further advance the fledgling concept that com-
partmentalization dictates the multifaceted effects of [Ca2+]i on
ASM contractile state.
Results and Discussion
Volatile Odorants Evoke Calcium Flux in Human ASM Cells. Odorant-
sensing GPCRs are the largest gene family in the human genome
(27) and are expressed on the smooth muscle of human bronchi
(17). The functional and physiological roles of olfactory recep-
tors expressed on ASM, and the ligands to which they respond,
are unestablished.
Using isolated human ASM cells, we characterized the direct
effects of 20 volatile chemicals comprised of ketones, aldehydes,
amines, alkenes, and alcohols (SI Appendix, Table S1), repre-
senting seven discrete odor types (i.e., putrid, nutty, fruity, floral,
caramellic, herbaceous, and minty). Because sensory transduc-
tion in the main olfactory epithelium primarily involves opening
of CNG, nonselective cation channels, and the consequent influx
of Ca2+ (27–29), we first assessed in ASM cells the signaling
properties of each odorous molecule. We used the FLIPR Cal-
cium 5 assay to measure [Ca2+]i and used a conventional, col-
orimetric cAMP ELISA to measure [cAMP]i.
In this space of odorants tested, eight odorants evoked a rapid
rise in [Ca2+]i (Fig. 1A). The [Ca
2+]i transients elicited by these
odorant subsets (e.g., citralva, β-ionone, hedione, lilial, nerol,
geraniol, eugenol, and ethyl vanillin) were similar to those
stimulated by histamine, an agent which causes ASM contraction
(Fig. 1A and SI Appendix, Fig. S1A). In contrast, compared to
vehicle control (0.1% dimethyl sulfoxide [DMSO]), we found
that two odorants tetramethylpyrazine and hedione appreciably
increased [cAMP]i in human ASM cells (SI Appendix, Fig. S1B,
ANOVA with Dunnet’s method, n = 4 to 6 independent sam-
ples). The magnitude of tetramethylpyrazine- and hedione-
induced [cAMP]i was similar to that elicited by the (prorelaxant)
β-agonist isoproterenol.
Volatile Odorants Have Diverse Effects on ASM Contractility. Using
OMTC, we next measured dynamic changes in cell stiffness in
response to volatile odorants, as an index of single-cell con-
tractility (7). Similar to the mechanical responses to histamine
and isoproterenol (i.e., contraction and relaxation) (7, 19), most
of the odorants (17/20) caused stiffness changes in individual
ASM cells (Fig. 1B). As shown in Fig. 1B, odorants occupying the
space of putrid smell (isovaleric acid, triethylamine, and pyrro-
lidine) markedly increased the stiffness of isolated human ASM
cells; the magnitude of cell stiffening was similar to that elicited
by histamine (SI Appendix, Fig. S1C). Conversely, odorants
spanning six nonmalodor types (i.e., nutty, fruity, floral, car-
amellic, herbaceous, and minty smells) decreased the cell stiff-
ness, similar to the effect of the β-agonist isoproterenol (Fig. 1B
and SI Appendix, Fig. S1C). Strikingly, and contrary to histamine-
induced [Ca2+]i associated with ASM contraction, non-
malodorous scents capable of increasing [Ca2+]i caused the re-
laxation of ASM cells (Fig. 1 and SI Appendix, Fig. S1). Together
these results established that the smooth muscle of human
bronchi has the capacity to chemically sense a wide range of
odorants with differing abilities to regulate bronchomotor tone
and ASM shortening.
In this space of nonmalodorous chemicals, a class of terpenoid
molecules (nerol, citronellol, eugenol, and linalool) are reported
ligands for various human and mouse olfactory receptors (26,
30–32). The monoterpene nerol, for example, is a cognate ligand
for the odorant receptor OR2W3 in human spermatozoa, and
elicits [Ca2+]i and sperm chemotaxis (24–26). Because terpenoid
molecules are known to possess antimicrobial, antiinflammatory,
and antispasmodic properties (33–36) that may serve therapeutic
functions in the management of obstructive lung diseases, we
focused herein on the physiological effects of the odorant nerol
and its mechanism of action through OR2W3 expressed on
human ASM cells.
The Monoterpene Nerol Evokes Calcium Signaling, Causes ASM
Relaxation, and Reverses Obstruction. In isolated human ASM
cells, the monoterpene nerol increased [Ca2+]i (Fig. 2A) and
caused ASM relaxation (Fig. 2B) in a dose-dependent manner,
with half maximal effective concentrations (EC50) of ∼526 μM
and ∼574 μM, respectively. The nerol EC50 values for [Ca2+]i
and ASM relaxation suggest a causal relationship between nerol-
evoked calcium signaling and ASM relaxation. In hPCLSs, nerol
(>500 μM) reversed carbachol-induced bronchoconstriction with
the patency of small airways equivalent to basal conditions (prior
to carbachol stimulation) (Fig. 2C). Fig. 2D showed the expected
between-lung and between-donor variations in nerol-induced
bronchodilation (12 lung slices derived from three different
nonasthmatic lung donors). Mixed effect analysis revealed sig-
nificant bronchodilatory responses to nerol at 1 mM and 3 mM,
resulting in ∼18.8 ± 7.6% and 47.0 ± 9.8% increase in the lu-
minal area from carbachol-constricted airways, respectively
(Fig. 2D). These results suggested that the monoterpene nerol
can bronchodilate and reverse airflow obstruction via its pro-
relaxant effects on ASM, involving calcium signaling.
Of note, exposure to nerol (500 to 1,000 μM), at both short
and long time scales, did not induce cAMP generation in human
ASM cells (SI Appendix, Fig. S2A). Moreover, nerol-induced
ASM relaxation was unaffected in cells treated with pharmaco-
logical inhibitors of adenylyl cyclase (SQ22536, 100 μM) and
protein kinase A (H89, 10 μM) (SI Appendix, Fig. S2B); cells






















treated with H89 exhibited significant (P < 0.001) increases in
baseline cell stiffness, suggesting the regulation of basal tone by
protein kinase A (PKA) (37). In addition, costimulation with
nerol and isoproterenol (β-agonist), both at submaximal doses,
induced ASM relaxation that was greater than that with either
compound alone (SI Appendix, Fig. S2 C and D). These data
showed that nerol-induced ASM relaxation is additive with
β-agonists, is not mediated by Gs signaling, and is independent of
PKA activity.
Nerol-Induced ASM Relaxation Is Not Mediated via TRP Channels. A
number of studies have reported that monoterpenes can act
upon the transient receptor potential (TRP) family of nonse-
lective cation channels, i.e., as agonist for TRPV1 (transient
receptor potential vanilloid 1) and agonist/antagonist for
TRPM8 (transient receptor potential melastatin 8) (38–40). In
our OMTC studies, we found that TRPM8 agonist menthol,
including TRPA1 [ankyrin (A) TRP channel] agonist allyl iso-
thiocyanate (AITC), markedly decreased the cell stiffness, but
not TRPV1 agonist capsaicin (SI Appendix, Fig. S3, as ascer-
tained by one-sample t test). Compared with vehicle control
(0.1% DMSO), the stiffness decrease in response to menthol was
evident within 10 s (P < 0.001 at t = 70 s) while evident within
29 s (P < 0.005 at t = 88.7 s) for AITC (ANOVA at each time).
None of the pharmacological antagonists decreased the cell
stiffness (SI Appendix, Fig. S3).
Of note, preexposing human ASM cells for 10 min with either
TRPM8 antagonist BCTC, TRPA1 antagonist HC-030031, or
TRPV1 antagonist capsazepine had little effects on nerol-
induced calcium signaling (Fig. 3A) and stiffness decreases
(Fig. 3B). Although we cannot rule out a possible role of other
TRP channels, these results suggested that nerol-induced ASM
relaxation does not invoke ligand-gated extracellular Ca2+ influx
and/or Ca2+ release through classical “pain”-, “temperature”-,
and “itch”-sensitive TRP channels (i.e., TRPV1, TRPM8, and
TRPA1). Based on these findings, we next assessed the mecha-
nism of action of the monoterpene nerol through its reported
odorant receptor OR2W3.
OR2W3 Is a Discriminatory GPCR Sensor for Terpenoid Odorants.
OR2W3 is one of the most highly abundant odorant-sensing
GPCR transcripts mapped to the human ASM olfactome (17).
We confirmed the presence of OR2W3 at the mRNA and pro-
tein levels in human ASM cells. As shown in Fig. 4A, we detected
the full-length OR2W3 mRNA at the expected 945 bp using
PCR; the PCR product was sequenced to confirm its identity.
Using qRT-PCR and Western blots, we validated the mRNA
and protein expressions of OR2W3 in ASM cells derived from
three different nonasthmatic lung donors (Fig. 4 B and C). The
specificity and sensitivity of primary antibodies used against
OR2W3 are shown in SI Appendix, Fig. S4. Using immunohis-
tochemistry, we also detected the expression of OR2W3 in hu-
man ASM cells (SI Appendix, Fig. S4 C and D). Of note, we
found that the transcript levels of OR2W3, as well as the extent
of ASM relaxation in response to nerol, were not significantly
different in cells derived from nonasthmatic (n = 6) vs. asthmatic
(n = 6) lung donors (Fig. 4 D and E).
In order to show that nerol-evoked ASM signaling and func-
tion are mediated through the odorant receptor OR2W3, we
next performed loss-of-function studies using short-hairpin (sh)
RNAs targeting OR2W3. As shown in Fig. 5A, shRNAs com-
plementary to OR2W3 mRNAs decreased OR2W3 transcripts in
human ASM cells (65 ± 3.0% reduction in shOR2W3-1 and 53 ±
6.0% in shOR2W3-2). The transcripts for other highly enriched
ASM ORs (e.g., OR1J1 and OR6A2) (17), including β2-adren-
ergic receptor (ADRB2), were unaffected in shOR2W3-1 and
shOR2W3-2 clones (Fig. 5A). Under these levels of
OR2W3 down-regulation, the magnitude of nerol-induced









































































































































Fig. 1. Intracellular calcium flux and single-cell contractility evoked by 20 volatile odorants. (A) Odorant-evoked [Ca2+]i was measured using FLIPR Calcium 5
assay. For each well of human ASM cells (∼30,000 cells/well), baseline Calcium 5 dye fluorescence was measured for the first 15 s, and after odorant addition
(t = 15 s), the fluorescent reading was continuously measured using a FlexStation 3. For vehicle control, [Ca2+]i was measured in response to 0.1% DMSO. As
positive control, cells were stimulated with 10 μM histamine. Data are presented as mean ± SE (n = 3 independent measurements). (B) Dynamic changes in the
stiffness of human ASM cells were measured in response to each odorant molecule using OMTC. For each individual human ASM cell, baseline stiffness was
measured for the first 60 s, and after odorant addition (t = 60 s), stiffness was continuously measured for the next 240 s. For each cell, stiffness was normalized
to its baseline stiffness prior to odorant stimulation (normalized baseline is indicated by dotted line). For vehicle control, stiffness was measured in response to
0.1% DMSO. As positive controls, cell were contracted with 10 μM histamine and relaxed with 10 μM isoproterenol. Data are presented as mean ± SE (n = 92
to 403 individual cell measurements). The colors indicated the odor types of 20 volatile chemicals (putrid, nutty, fruity, floral, caramellic, herbaceous, and
minty); the concentrations used for each odorant molecule are shown in SI Appendix, Table S1.




























calcium signaling displayed a varied effect at below EC50 values
(e.g., 125 to 250 μM). Both shOR2W3-1 and shOR2W3-2,
however, showed appreciable attenuations in nerol-induced
[Ca2+]i (peak) and ASM relaxation compared to that of scram-
ble shRNA control (Fig. 5 B and C). Of note, in both clones,
ASM relaxation responses to nerol were markedly attenuated in
all concentrations of nerol tested, except 1 mM (SI Appendix,
Fig. S5C). These results suggested that, in human ASM cells, the
physiological responses to the monoterpene nerol are tranduced
in part by the activation of its reported odorant-sensing
OR2W3 (26).
To further characterize the potential receptor-ligand interac-
tions of the odorant receptor OR2W3 with its reported ligand
nerol, we also applied a recently described method called
DREAM (deorphanization of receptors based on expression
alterations in mRNA levels) (41, 42). This method identifies the
cognate receptor-ligand pairs through dynamic alterations of the
receptor transcripts (42). Human ASM cells exposed to nerol
showed decreases in OR2W3 transcripts that were dose and time
dependent, with the maximal effects at 1 mM and at 24 h (SI
Appendix, Fig. S5 A and B). Nerol exposure had little effect on
the transcript levels of OR1J1 and OR6A2 (SI Appendix, Fig.
S5 B and C). Interestingly, the monocyclic monoterpene eugenol
also decreased OR2W3 transcripts in human ASM cells, whereas
monoterpenoids L-menthone (monoterpene ketone) and euca-
lyptol (monoterpene oxide) did not (SI Appendix, Fig. S5C). In
addition, human ASM cells exposed to geraniol (a geometric
isomer of nerol) and citronellol (dihydrogeraniol) showed
marked reductions in OR2W3 mRNAs, but not to linalool (a
structural isomer of nerol/geraniol). Together these data pro-
vided further support that OR2W3 expressed on human ASM
cells is a monoterpene-activated olfactory GPCR.
OR2W3-Evoked Ca2+ Flux Is Functionally Divergent from That of
TAS2Rs. In human ASM cells, TAS2Rs signal to phospholipase
C (PLCβ) and produce a localized Ca2+ release, membrane
hyperpolarization, and smooth muscle relaxation partially
through large conductance BKCa channels (19, 20). Accordingly,
we examined whether OR2W3-induced ASM relaxation may
also involve a compartmentalized Ca2+ signal.
To this end, we employed selective pharmacological inhibitors





Fig. 2. Nerol evokes calcium flux, ASM relaxation, and bronchodilation. (A) Nerol-evoked [Ca2+]i and EC50 of [Ca
2+]i response in isolated human ASM cells.
Data are presented as mean ± SE (n = 90 to 123 cells per group). (B) Nerol-induced stiffness changes and EC50 of stiffness response. Data are presented as
mean ± SE (n = 124 to 219 individual cell measurements). (C) Representative images of small airways before and after constricted with 10 μM carbachol (for 10
min), followed by stimulation with increasing doses of nerol (5 min for each dose). After nerol exposures, lung slices were relaxed with forskolin (1 μM) as
positive control. (D) Individual hPCLS responses to increasing doses of nerol. Nerol-induced bronchodilation was measured in a total of 12 hPCLSs derived from
three different nonasthmatic lung donors. To control for random effects from multiple lung slices from the same donor, we applied a linear mixed effect
model using SAS V.9.2 (SAS Institute). ns, not significant.






















for PLCβ), including iberiotoxin and charybdotoxin for BKCa
channels (19, 20). In addition, we measured nerol-induced ASM
relaxation under experimental conditions in which internal stores
were depleted of calcium with thapsigargin (19, 43). Nerol-
induced ASM relaxation was not inhibited by pharmacological
inhibitions of Gβγ, PLCβ, and BKCa channels (Fig. 6A), nor de-
pleting intracellular calcium stores with thapsigargin (Fig. 6B).
While U73122 treatment had little effect on the cell stiffness or
nerol-induced stiffness decreases (Fig. 6A), it markedly reduced
[Ca2+]i transients evoked by nerol (SI Appendix, Fig. S6A). These
findings suggest that OR2W3-evoked calcium release through
PLCβ is necessary, but not sufficient to cause ASM relaxation.
Interestingly, nerol-stimulated increases in [Ca2+]i and the
associated relaxation of ASM cells were completely inhibited by
chelating extracellular calcium with ethylene glycol-bis(β-ami-
noethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA) (Fig. 6B and
SI Appendix, Fig. S6B); depleting intracellular calcium stores had
little effects. As expected, depleting intracellular stores markedly
inhibited [Ca2+]i transients and ASM contraction induced by
Gq-coupled receptor agonist histamine (Fig. 6B and SI Appendix,
Fig. S6B). These results showed that OR2W3-dependent ASM
responses require extracellular Ca2+ influx, suggesting a mech-
anism distinct from Ca2+ signal tranduced by TAS2Rs. Consis-
tent with this notion, costimulation with submaximal doses of
nerol and chloroquine (TAS2R agonist) showed enhanced re-
laxation responses relative to that caused by stimulation with
either compound alone (SI Appendix, Fig. S6C).
Chemosensory OR2W3 Responses Are Associated with Depolarization
of the Cell Membrane. Contrary to the regulation of E-C coupling
in smooth muscle by other prorelaxant agents (19, 44, 45), nerol-
mediated ASM relaxation was accompanied by depolarization of
A B






























































Fig. 3. The role for classical pain-, temperature-, and itch-sensitive TRP channels on nerol-induced ASM responses. Human ASM cells were treated for 10 min
with 5 μM BCTC, 30 μM HC-030031, or 5 μM capsazepine, and then stimulated with 1 mM nerol. For vehicle control, cells were treated for 10 min with 0.1%
DMSO. Nerol-induced [Ca2+]i (A) and stiffness changes (B) were measured using Fura-2 and OMTC, respectively. Data are presented as mean ± SE (A, n = 94 to





































































Fig. 4. Human ASM cells express OR2W3. (A) Expression of OR2W3 transcripts in human ASM cells was detected using PCR with (+) or without (−) reverse
transcriptase. Full-length OR2W3 is indicated at 945 bp. (B) PCR was also applied to RNAs isolated from cells derived from three additional nonasthmatic lung
donors (N1 to N3); PCR products were subsequently run on an agarose gel with or without reverse transcriptase. (C) Protein expression of OR2W3 (35 kDa) was
assessed by Western blot in human ASM cells derived from three nonasthmatic lung donors (N1 to N3). Tubulin (50 kDa) was used as loading control. (D)
Transcript levels of OR2W3 and (E) nerol-induced ASM relaxation in cells derived from six nonasthmatic and six asthmatic lung donors. Group mean of nerol-
induced ASM relaxation is presented as percent change from the respective baseline stiffness.




























the cell membrane (Fig. 6C). As expected, the bitter tastant chlo-
roquine caused membrane hyperpolarization while the contractile
agonist histamine caused membrane depolarization in human ASM
cells (Fig. 6D). Nerol-induced plasma membrane depolarization
was not due to cell injury as the concentrations of nerol tested
(125 μM to 1 mM) were significantly below the concentrations
producing 50% toxicity (IC50) (SI Appendix, Fig. S6D). These re-
sults showing ASM relaxation despite increases in [Ca2+]i and
membrane depolarization suggested an unappreciated functional di-
versity of Ca2+ signaling in the regulation of E-C coupling in ASM.
OR2W3-Evoked Membrane Depolarization Is Linked to SOCE Pathway.
To explore the dichotomy of OR2W3-evoked chemosensory
responses, we applied pharmacological blockers of Ca2+-selec-
tive cation channels that are involved in the E-C coupling
mechanisms in smooth muscle (44, 46), as well as potent inhib-
itors of Ca2+- and cAMP-activated channels that are involved in
the induction and adaptation of olfaction (29, 47).
In human ASM cells, treatment with the CNG channel blocker
L-cis diltiazem or the adenylyl cyclase inhibitor SQ22536 had
little effect on nerol-induced [Ca2+]i (peak) and ASM relaxation
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Fig. 5. OR2W3-evoked calcium flux causes ASM relaxation. (A) Short hairpin RNAs complementary to OR2W3 mRNAs markedly knockdown OR2W3, but not
other ORs and β2-adrenergic receptor (ADRB2) in human ASM cells. Data are presented as mean ± SE (n = 3 independent measurements). We used
Kruskal–Wallis test and applied Dunn’s method for multiple comparisons. P values indicate the statistical differences from shControl. (B) Peak [Ca2+]i and (C)
stiffness changes to nerol in shOR2W3 vs. shControl cells. Data are presented as mean ± SE (control shRNA, n = 282 to 377; OR2W3 shRNA #1, n = 266 to 368;
OR2W3 shRNA #2, n = 210 to 345 individual cell measurements). (B and C) We used ANOVA with adjusting for multiple comparisons by applying the Dunnet’s
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Fig. 6. OR2W3-evoked ASM relaxation is divergent from TAS2R signaling and accompanies membrane depolarization. (A) Human ASM cells were treated for
10 min with gallein (20 μM), U73122 (1 μM), iberiotoxin (10 nM), or charybdotoxin (10 nM), and then stimulated with 1 mM nerol. For vehicle control, cells
were treated for 10 min with 0.1% DMSO. For each treatment group, baseline stiffness was measured for the first 60 s, and after nerol addition (t = 60 s,
arrow), stiffness was continuously measured for the next 240 s. To satisfy the normal distribution assumptions associated with ANOVA, cell stiffness data
(steady-state baseline and nerol-induced stiffness) were converted to log scale prior to analyses. Data are presented as mean ± SE (n = 140 to 306 individual
cell measurements). (B) To chelate extracellular calcium, human ASM cells were treated for 10 min with 2 mM EGTA. To deplete calcium from the intracellular
stores, human ASM cells were treated for 20 min with 10 μM thapsigargin (19, 43). ASM cells were then stimulated with 1 mM nerol or 10 μM histamine. Data
are presented as mean ± SE (n = 157 to 270 individual cell measurements). We used ANOVA with adjusting for multiple comparisons by applying the Dunnet’s
method. Treatment groups (EGTA and thapsigargin) were compared with respective Controls for nerol or histamine stimulation. (C) Dynamic changes in
membrane potential with increasing doses of nerol added at 30 s (arrow) and followed up to 250 s. (D) Membrane potential (area under curve, AUC) evoked
by nerol in comparison to 10 μM histamine (His) and 1 mM chloroquine (CQ). Data are presented as mean ± SE (n = 3 independent measurements). *P < 0.05,
**P < 0.01, ***P < 0.001, ****P < 0.0001 (unpaired t test). ns, not significant.






















(SI Appendix, Fig. S7A). Human ASM cells treated with L-cis
diltiazem showed modest increases in [Ca2+]i (9.6 ± 5.8% from
untreated cells) and muscle relaxation (13.8 ± 5.6% from un-
treated cells) in response to nerol. In addition, nerol-stimulated
ASM relaxation was significantly augmented in cells treated with
the BKCa channel inhibitor iberiotoxin (SI Appendix, Fig. S7A).
These results provided a further support that nerol-induced
ASM relaxation is not mediated by PKA activity or opening of
the BKCa channels and is independent of Ca
2+ flux through
CNG channels. Of note, we found that pharmacological inhibi-
tion of the store-operated calcium channel (SOC) component
Orai1 with MRS1845 (48), but not of L-type Ca2+ channels with
verapamil, inhibited both nerol-evoked increases in [Ca2+]i and
ASM relaxation (SI Appendix, Fig. S7A). SOC inhibition also
markedly attenuated nerol-induced plasma membrane depolar-
ization in human ASM cells (SI Appendix, Fig. S7B). These data
suggest that nerol-evoked Ca2+ flux and the associated ASM
relaxation involve store-operated calcium entry (SOCE) pathway
and membrane depolarization, at the junction between plasma
membrane and the ER (49, 50).
Chemosensory Mechanism of OR2W3 Is Tuned to Ca2+-Activated Cl−
Channels. Recently, Li et al. (51) have demonstrated a role for
calcium-activated chloride (CaC) channels (Anoctamin 2
[ANO2] or TMEM16B), and the Cl− current, in chemosensory
signal amplification of olfactory transduction in mice. The
TMEM16 family of membrane proteins is now considered a bona
fide Ca2+-activated Cl− channel (52–54). Of note, ANO1
(TMEM16A) is broadly expressed (55–59) and, in ASM,
TMEM16A expression and activity, but not TMEM16B, modu-
late smooth muscle tone and shortening (56, 60, 61).
Human ASM cells treated with a pharmacological inhibitor of
TMEM16A (100 μM CaCCinh-A01) showed complete reversal
of membrane potential in response to nerol (Fig. 7A). In addi-
tion, consistent with earlier studies using tissues (56, 60, 61), cells
treated with CaCCinh-A01 (100 μM) exhibited appreciable de-
creases in baseline cell stiffness and showed marked decreases in
cell stiffening responses to histamine (Fig. 7B). Consequently,
under these conditions, nerol-induced ASM relaxation was
completely ablated (Fig. 7C). As this may be attributable to the
maximal relaxation of ASM cells caused by TMEM16A inhibi-
tion (i.e., no head room left to observe further decreases in
stiffness in response to nerol), we lowered the concentration of
CaCCinh-A01 (10 μM) pretreatment. Cells treated with 10 μM
CaCCinh-A01 exhibited the level of baseline cell stiffness that
was comparable to that of untreated cells; and, both showed a
similar magnitude of cell stiffening response to histamine
(Fig. 7B). The subsequent ASM relaxation responses to nerol,
however, were markedly attenuated in cells treated with 10 μM
CaCCinh-A01 (Fig. 7C). These results suggested a close prox-
imity of TMEM16A activation, in time and space, to a macro-
molecular signaling complex that may be comprised of the
assembly of store-operated calcium channel Orai1 and the ER-
resident stromal interaction molecule 1 (STIM1) (49, 50). The
question then becomes how such signal amplification or elec-
trical responses lead to ASM relaxation.
Using MQAE halide ion-quenched fluorescent indicator, we
assessed whether nerol-activated CaC channels cooperatively
invoke the electroneutral cation-chloride exchangers (Na+-K+-
Cl− cotransporter 1, NKCC1) and the consequent intracellular
Cl− accumulation (56). As a positive control, NaI induced halide
into ASM cells in a dose-dependent manner, which was blocked









































































































Fig. 7. OR2W3-evoked chemosensory responses are tuned to Ca2+-activated Cl− channels. (A) Nerol-induced changes in membrane potential were measured
in cells treated with Ca2+-activated Cl− (CaC) channel inhibitor (100 μM CaCCinh-A01). For vehicle control, cells were treated with 0.1% DMSO. Arrow indicates
time (t = 20 s) at which nerol was added. Data are presented as mean ± SE (n = 3 independent measurements). ****P < 0.0001 (area under the curve [AUC],
unpaired t test). (B) Human ASM cells were treated for 10 min with or without CaCCinh-A01 (10 and 100 μM) and then contracted with 10 μM histamine
(histamine was added at t = 60 s, arrow). Data are presented as mean ± SE (n = 228 to 326 cells). ANOVA was applied after data transformation. *P < 0.05. (C)
Histamine-contracted cells were subsequently stimulated with 1 mM nerol. For each individual cell, stiffness was normalized to its stiffness prior to nerol
stimulation (nerol was added at t = 60 s, arrow). Data are presented as mean ± SE (n = 182 to 319 individual cell measurements). RFU, relative
fluorescence units.




























Appendix, Fig. S7C). Nerol had little effect on halide flux in cells
treated with or without NPPB; MQAE fluorescent intensities
were similar between vehicle (control)- and nerol-stimulated
cells (SI Appendix, Fig. S7C). Moreover, nerol-evoked ASM re-
laxation was not inhibited by bumetanide, a pharmacological
blocker of NKCC1 (SI Appendix, Fig. S7D), that is involved in
the regulation of cell volume and in the accumulation of intra-
cellular Cl− (62). These results showed that nerol-evoked ASM
relaxation is not facilitated by intracellular Cl− accumulation
and/or involves the electroneutral NKCC1 belonging to the
SLC12A family of cation-chloride cotransporters.
TMEM16A Cooperates with CFTR to Relax ASM. In differentiated
airway epithelial cells, TMEM16A is indispensable for the apical
expression of cystic fibrosis transmembrane conductance regu-
lator (CFTR) (63). CFTR is another major secretory anion
channel whose defect leads to cystic fibrosis (CF) (64). In human
ASM cells, CFTRs are localized to the sarco(endo)plasmic re-
ticulum (65) and are in close proximity to the same micro-
domains that comprise the assembly of Ca2+ and cAMP
signaling proteins, including Orai1-STIM1 complex regulating
SOCE (49, 50). Most recently, Bozoky et al. (66) reported that
CFTR can be directly activated by calcium signaling, indepen-
dent of PKA phosphorylation. Based on these earlier studies, we
considered whether mechanisms of nerol-induced ASM relaxa-
tion entail direct activation of CFTR via OR2W3-evoked
regulation of [Ca2+]i.
To this end, we treated isolated human ASM cells for 10 min
with or without 100 μM of the CFTR inhibitor CFTRinh-172 and
subsequently measured dynamic changes in cell stiffness in re-
sponse to either 10 μM isoproterenol (Fig. 8A), 250 μM chlo-
roquine (Fig. 8B), or 1 mM nerol (Fig. 8C). As shown in Fig. 8,
while CFTRinh-172 had little effect on isoproterenol- or
chloroquine-induced ASM relaxation, CFTRinh-172 marked
attenuated nerol-induced ASM relaxation. On the other hand,
nerol-induced ASM relaxation was enhanced in cells treated for
30 min with the CFTR-gating potentiator ivacaftor (SI Appendix,
Fig. S8A). These results established that the mechanism of nerol-
induced ASM relaxation is distinct from that of β2AR and
TAS2R pathways, suggesting a role for calcium sequestration
through CFTRs expressed on the sarco(endo)plasmic reticulum
in human ASM cells. Of note, nerol alone or in combination with
ivacaftor (30-min pretreatment) had little effect on the stiffness
of human ASM cells derived from a CF lung donor with ΔF508
deletion in CFTR gene (SI Appendix, Fig. S8B). Taken together,
these results are consistent with a mechanistic framework in
which nerol-induced ASM relaxation requires cooperative acti-
vation of TMEM16A and CFTR to compartmentalize Ca2+
signaling within discrete cellular microdomains, including the
sequestration of calcium through CFTRs expressed on the
endo(sarco)plasmic reticulum of human ASM cells (Fig. 9).
Conclusion
We showed that the monoterpene nerol evokes calcium flux and
causes smooth muscle relaxation through OR2W3 expressed on
human ASM cells. Paradoxically, we demonstrated that OR2W3-
stimulated relaxation of ASM cells requires Ca2+ influx and
plasma membrane depolarization, and that these chemosensory
mechanisms are predominated by a cooperative activation of
TMEM16A and CFTR. These observations reveal a previously
unrecognized sensory GPCR circuitry in human ASM cells and
identify multiple points for signal amplification, attenuation, and
duration of chemosensory responses localized to discrete cellular
microdomains. Importantly, our study uncovers a surprising role
for localized Ca2+ regulation that affects E-C coupling mecha-
nisms in human ASM cells.
Methods
Materials.Unless otherwise stated, all odorants of the highest purity available
were purchased from Sigma-Aldrich (SI Appendix, Table S1). Odorants were
freshly prepared on each day of the experiments; they were first recon-
stituted in DMSO and serially diluted in the appropriate buffer or media. The
following pharmacological inhibitors were reconstituted in DMSO, kept
at −20 °C, and diluted in the appropriate buffer or media prior to experi-
ments: gallein, U73122, iberiotoxin, charybdotoxin, MRS1845, CaCCinh-A01,
H89, CFTRinh-172 (all from Tocris), SQ22536 (Abcam), L-cis diltiazem (Enzo
Life Sciences), verapamil (Sigma), and ivacaftor (VX-770, Selleck).
Human ASM Cell Culture. Human ASM cultures were established from the
proximal airways (first through third order bronchi) of deceased donor lungs
unsuitable for transplantation in accordance with the Institutional Review
Boards at Rutgers University. Cells were cultured in Dulbecco’s Modified
Eagle Medium-Ham’s F-12 medium (1:1 vol/vol) supplemented with 10%
fetal bovine serum (FBS), antibiotics (100 U/mL penicillin, 100 μg/mL strep-
tomycine), and 2.5 μg/mL amphotericin-β. As described elsewhere (7), cells
were grown until confluence at 37 °C in humidified air containing 5% CO2
and then maintained in serum-free media for at least 24 h prior to all ex-
periments. In this study, cells were used at or before passage 6.
Generation of PCLS and Bronchodilation Assays. hPCLSs were prepared as
previously described (67, 68). In brief, whole human lungs from three non-
asthmatic donors were dissected and inflated using 2% (wt/vol) low melting
point agarose. Once the agarose set, the lobe was section, and cores of
8-mm diameter were made. The cores that contained a small airway by vi-
sual inspection were sliced at a thickness of 350 μm (Precisionary Instruments
VF300 Vibratome) and collected in wells containing supplemented Ham’s F-
12 medium. Suitable airways (≤1-mm diameter) on slices were selected on
the basis of the following criteria: presence of a full smooth muscle wall,
presence of beating cilia, and unshared muscle walls at airway branch points
to eliminate possible counteracting contractile forces. Each slice contained
∼98% parenchyma tissue; hence, all airways situated on a slice had sufficient
parenchymal tissue to impart basal tone. Adjacent slices containing contig-
uous segments of the same airway were paired and served as controls and
were incubated at 37 °C in a humidified air-CO2 (95 to 5%) incubator. Sec-
tions were rinsed with fresh media two to three times on day 1 and day 2
to remove agarose and endogenous substances released that variably
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Fig. 8. OR2W3-induced ASM relaxation is inhibited by pharmacological blockers of CFTR. (A–C) Human ASM cells were treated with or without 100 μM
CFTRinh-172 for 10 min. Using OMTC, we measured the stiffness changes in response to A 10 μM isoproterenol, (B) 250 μM chloroquine, and (C) 1 mM nerol.
For each individual cell, stiffness changes were normalized to its respective baseline stiffness. Data are presented as mean ± SE (A, n = 97 to 168; B, n = 144 to
145; C, n = 52 to 185 individual cell measurements).






















confound the production of inflammatory mediators and/or alter airway
tone (67, 68). Airways were bronchoconstricted to carbachol (10−5 M), fol-
lowed by sequential stimulation with increasing doses of nerol (250 μM,
500 μM, 1 mM, and 3 mM) and then forskolin (10−5 M).
To assess luminal area, lung slices were placed in a 12-well plate in media
and held in place using a nylon weight with platinum attachments. The
airway was located using a microscope (Nikon Eclipse; model no. TE2000-U;
magnification, ×40) connected to a live video feed (Evolution QEi; model no.
32-0074A-130 video recorder). Airway luminal area was measured using
Image-Pro Plus software (version 6.0; Media Cybernetics) and represented in
units of square micrometers (67, 68). Bronchodilation was calculated as the
percent reversal of maximal bronchoconstriction.
Quantitative Reverse Transcription PCR (qRT-PCR). RNA was extracted from
human ASM cells using the RNeasy Mini Kit (Qiagen) and digested with
RNase-free DNase (Qiagen) according to the manufacturer’s protocol. RNA
was reverse transcribed using the High-Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Fisher Scientific), and no-enzyme controls (in which
the reverse transcriptase was replaced with water) were made concurrently.
Real-time PCR was performed using TaqMan probes for OR2W3 or SYBR
green primers for OR2W3 (forward: 5′ CTGCCGGGGCTTGGTGTCAG 3′, re-
verse: 5′ TCCACCTCGTGGTGCCCACA 3′) using a StepOne real-time PCR sys-
tem (Thermo Fisher).
PCR. PCR was performed with TaKaRa Taq DNA Polymerase (Clontech) at an
annealing temperature of 50 °C to amplify the full-length OR2W3. To verify
the product size, PCR products were visualized by UV after ethidium bro-
mide staining on agarose gels.
Immunocytochemistry. Human ASM cells were seeded on 12-mm glass cov-
erslips (VWR) at 30,000 cells/coverslip. The adherent cells were fixed with 4%
paraformaldehyde in phosphate-buffered saline (PBS) for 20 min, washed
three times in PBS, and permeabilized with 0.2% Triton X-100 (Bio-Rad) for
15 min at room temperature. Coverslips were then blocked with 2% bovine
serum albumin (BSA) in PBS for 1 h at room temperature and incubated
overnight at 4 °C with mouse anti-OR2W3 primary antibody (1:300, Sigma).
Subsequently, coverslips were incubated with an Alexa Fluor goat anti-
mouse 488 (1:400, The Jackson Laboratory) for 1 h at room temperature.
Coverslips were washed three times with 2% BSA in PBS and mounted with
ProLong Gold Antifade Mountant with DAPI (Thermo Fisher). Samples were
imaged at 20× magnification.
The sensitivity of the OR2W3 antibody (Sigma) was tested by transfecting
HEK 293T cells with Flag-tagged OR2W3 or Flag-tagged Olfr78, as we have
previously done for OR trafficking and surface localization studies (17, 69,
70). This consisted of first staining live nonpermeabilized cells with rabbit
polyclonal anti-Flag antibody (Sigma) at 4 °C. Cells were then fixed,
permeabilized, and stained with mouse anti-OR2W3 primary antibody
(1:300, Sigma). Primary antibodies were detected using Alexa Fluor goat
anti-rabbit 555 (for surface OR) and goat anti-mouse 488 (for internal OR)
secondary antibodies, and nucleus was stained with Hoechst 33342 (1:2,500).
Western Blotting. Cells were grown in six-well plates to confluency, followed
by 24-h serum deprivation. Serum-deprived cells were washed with PBS and
lysed with 1× SDS Protein Gel Loading Solution (Quality Biological, Inc.).
Proteins were separated by SDS/PAGE and transferred to nitrocellulose
membranes. Membranes were blocked with 5% BSA in Tris-buffered saline
with 0.1% Tween 20, and incubated with primary antibodies overnight
(OR2W3 [1:1,000; GeneTex] and tubulin [1:500; Sigma]), followed by HRP-
conjugated secondary antibody for 1 h. HRP-labeled bands were detected
using an enhanced chemiluminescence (ECL) kit (Pierce) according to the
manufacturer’s instructions. The specificity of the OR2W3 antibody (Gene-
Tex) was verified by blocking peptide competition assay.
Calcium Imaging. Intracellular calcium ([Ca2+]i) for the initial odor screen was
quantified using the FLIPR Calcium 5 assay kit (Molecular Devices). Human
ASM cells were seeded at 30,000 cells/well in collagen I-coated wells (96-well
black-well/clear-bottom plates, Corning) in serum-free media. Cells were
incubated with Calcium 5 dye for 1 h at 37 °C and subsequently allowed to
recover at room temperature for 15 min. Odorants were added, and fluo-
rescent readings were measured using a FlexStation 3 (Molecular Devices).
Hanks’ balanced salt solution (HBSS) adjusted to a pH of 7.4 and supple-
mented with 20 mM Hepes was used during the experiments and as a buffer
to dilute the Calcium 5 dye.
For [Ca2+]i imaging in individual cells, ratiometric calcium indicator Fura-2
was used under the same experimental condition as FLIPR calcium imaging.
In brief, cells were incubated with 2 μM Fura-2 for 45 min, washed three
times with buffer, and incubated for another 30 min without Fura-2 prior to
imaging. Cells were imaged sequentially at 340 nm and 380 nm, and 30 to 45
cells per field of view were used to calculate the 340/380 ratio. The buffer
used to dilute Fura-2 and during the course of the experiment was HBSS
supplemented with 10 mM Hepes, 11 mM glucose, 2.5 mM CaCl2, and
1.2 mM MgCl2 (pH adjusted to 7.4). Calcium-free medium was similarly
made, with the exclusion of CaCl2.
cAMP Assay. Primary human ASM cells seeded in six-well plates were incu-
bated in lysis buffer for 20 min at 4 °C and dissociated using cell scrapers. Cell
samples were subsequently centrifuged at 16,100 rcf for 10 min, and
supernatants were collected. Protein concentrations were measured using a
Pierce BCA protein assay kit (Thermo Scientific). Diluted samples and cAMP
standards were acetylated for increased sensitivity, and cAMP concentra-
tions were measured using a colorimetric cAMP ELISA kit (Cell Biolabs)























Airway Smooth Muscle Relaxa
Fig. 9. Conceptual model of OR2W3-evoked ASM relaxation and bronchodilation. Activation of the odorant receptor OR2W3, a GPCR expressed on human
ASM cells causes Ca2+ release through PLCβ-IP3 signaling leading to decline in Ca2+ in the intracellular store [endo(sarco)plasmic reticulum, ER/SR]. The re-
duction in ER Ca2+ initiates extracellular calcium influx through the SOCE pathway via activation of Stim1 and its subsequent physical interactions with Orai1
at the discrete cellular microdomains. Ca2+ flux through store-operated calcium channels leads to plasma membrane depolarization and is potentiated by a
cooperative activation of TMEM16A and CFTR localized at the same junction between plasma membrane and the ER/SR. The action of the latter causes Cl−
uptake into the SR, facilitating Ca2+ sequestration that results in a decrease in cytosolic calcium concentration promoting ASM relaxation.




























OMTC. Dynamic changes in cell stiffness were measured as an indicator of the
single-cell contraction and/or relaxation of isolated human ASM cells as we
have previously described (7). In brief, RGD-coated ferrimagnetic microbeads
(4.5 μm in diameter) bound to the cytoskeleton through cell surface integrin
receptors were magnetized horizontally and then twisted in a vertically
aligned homogeneous magnetic field that was varying sinusoidally in time.
This sinusoidal twisting magnetic field caused both a rotation and a pivoting
displacement of the bead: as the bead moves, the cell develops internal
stresses which in turn resist bead motions (71). Lateral bead displacements in
response to the resulting oscillatory torque were detected with a spatial
resolution of ∼5 nm, and the ratio of specific torque to bead displacements
was computed and expressed here as the cell stiffness in units of Pascal per
nanometer (Pa/nm).
Short Hairpin RNA-Mediated OR2W3 Silencing. Bacterial glycerol stocks of two
precloned short hairpin RNAs (shRNAs), each targeting a different region of
the human OR2W3 gene, were obtained from the Sigma TRC 1.5 shRNA li-
brary (TRCN0000204524 and TRCN0000187944 from The RNAi Consortium,
Sigma). A control shRNA that has the same pLKO.1 plasmid was also used.
Bacteria from glycerol stocks were streaked onto an LB agar plate and
grown overnight at 37 °C. A single colony from each plate was inoculated in
liquid LB with ampicillin (100 μg/mL), and plasmid DNA was isolated using
the QIAGEN Plasmid Midi Kit (Qiagen) per manufacturer’s protocol. To
produce lentivirus, the plasmid DNA was cotransfected into HEK 293T cells
with packaging plasmids pMD2.G and psPAX2 (Addgene) using the calcium
phosphate transfection method in 100 mm cell culture dishes. Lentivirus was
harvested 48 h after transfection and filtered through a 0.45-μm cellulose
acetate filter (Sigma). The packaged lentivirus was then transduced into
ASM cells using T25 flasks, followed by puromycin selection for 2 to 3 d. The
surviving cells were used for subsequent experiments to test knockdown
efficiency and cell function.
Membrane Potential. Changes in membrane potential were measured using
the FLIPR Membrane Potential Assay Kit Blue (Molecular Devices). In brief,
human ASM cells seeded at 40,000 cells/well in 96-well plates were incubated
with dye in HBSS supplemented with 20 mM Hepes for 10 min at 25 °C in the
dark. Fluorescence signals were measured using a FlexStation 3 (Molecular
Devices), with baseline fluorescence (excitation 530 nm, emission 565 nm,
cutoff 550 nm) measurements taken for 16 s before addition of agonists.
Signals were acquired every 2 s for a total of 2 min. An increase or decrease
in fluorescence after cell stimulation indicates cell membrane depolarization
or hyperpolarization, respectively.
LDH Toxicity Assay. Primary human ASM cells adherent on 96-well plates were
incubated with 125 to 3,000 μM nerol for 1 h and 24 h, and the release of
lactose dehydrogenase (LDH) was measured using the Pierce LDH Cytotox-
icity Assay Kit (Thermo Fisher) according to the manufacturer’s protocols.
Halide Flux Measurement. Primary human ASM cells were seeded at 10,000
cells/well in collagen I-coated 96-well, black-well plates, and cultured over-
night. The next day, cells were incubated with 10 mM MQAE (Invitrogen) in
serum-free media for 10 h at 37 °C. Cells were washed three times with
physiological buffer solution (10 mM Hepes pH 7.4, 10 mM glucose, 2.4 mM
K2PO4, 0.6 mM K2HPO4, 1 mM MgSO4, 1 mM CaSO4, and 110 mM sodium
isethionate) and were subsequently loaded with either 100 μM chloride
channel blocker or 0.1% DMSO vehicle in 100 μL physiological buffer for
30 min. Changes in the fluorescence intensity of MQAE indicator quenched
by halide ion was measured with a FlexStation 3 device (Molecular Devices).
Baseline fluorescence (excitation 360 nm, emission 460 nm, cutoff 455 nm)
measurements were taken every 2 s for a total of 2 min, and after addition
of either nerol or NaI (as a positive control), changes in the fluorescence
were continuously recorded for an additional 3 min. A decline in fluores-
cence after adding agonists indicates accumulation of halide ions inside
the cells.
Data Analysis. Unless otherwise stated, data are presented as mean ± SEM.
Statistical comparisons were done with two-tailed, unpaired Student’s
t tests, as well as the analysis of variance (ANOVA) with adjusting for mul-
tiple comparisons by applying the Dunnett’s method. Analyses were per-
formed using GraphPad Prism, and two-sided P values less than 0.05 were
considered significant.
Data Availability. All study data are included in the article and supporting
information.
ACKNOWLEDGMENTS. This work was supported by the New Jersey Alliance
for Clinical and Translational Science (UL1TR0030117) and the National
Institutes of Health grants: P01HL114471 (to S.S.A., R.B.P., S.B.L., and R.A.P.),
R01HL137030 (to D.A.D.), R01HL058506 (to R.B.P.), R01NS054791 (to X.D),
and R01AI135186 (to X.D.). X.D. is an investigator of the Howard Hughes
Medical Institute. S.S.A. was also supported by a Discovery Award and a
Catalyst Award from Johns Hopkins University, the Patrick C. Walsh Prostate
Cancer Research Fund from the James Buchanan Brady Urological Institute
(The Frank E. Rath Spang & Company Charitable Trust Scholar), and Mary-
land Cigarette Restitution Fund from the State of Maryland Department of
Health and Mental Hygiene.
1. M. Masoli, D. Fabian, S. Holt, R. Beasley; Global Initiative for Asthma (GINA) Program,
The global burden of asthma: Executive summary of the GINA dissemination com-
mittee report. Allergy 59, 469–478 (2004).
2. P. J. Sterk, E. H. Bel, Bronchial hyperresponsiveness: The need for a distinction be-
tween hypersensitivity and excessive airway narrowing. Eur. Respir. J. 2, 267–274
(1989).
3. A. J. Woolcock, J. K. Peat, Epidemiology of bronchial hyperresponsiveness. Clin. Rev.
Allergy 7, 245–256 (1989).
4. S. S. An et al., Airway smooth muscle dynamics: A common pathway of airway ob-
struction in asthma. Eur. Respir. J. 29, 834–860 (2007).
5. J. L. Black, P. R. Johnson, Airway smooth muscle in asthma. Respirology 1, 153–158
(1996).
6. G. G. King, P. D. Paré, C. Y. Seow, The mechanics of exaggerated airway narrowing in
asthma: The role of smooth muscle. Respir. Physiol. 118, 1–13 (1999).
7. S. S. An et al., An inflammation-independent contraction mechanophenotype of
airway smooth muscle in asthma. J. Allergy Clin. Immunol. 138, 294–297.e4 (2016).
8. O. Kilic et al., A microphysiological model of the bronchial airways reveals the in-
terplay of mechanical and biochemical signals in bronchospasm. Nat. Biomed. Eng. 3,
532–544 (2019).
9. P. J. Barnes, New drugs for asthma. Nat. Rev. Drug Discov. 3, 831–844 (2004).
10. S. J. Morgan et al., β-Agonist-mediated relaxation of airway smooth muscle is protein
kinase A-dependent. J. Biol. Chem. 289, 23065–23074 (2014).
11. M. R. Sears et al., Regular inhaled beta-agonist treatment in bronchial asthma. Lancet
336, 1391–1396 (1990).
12. H. S. Nelson, S. T. Weiss, E. R. Bleecker, S. W. Yancey, P. M. Dorinsky; SMART Study
Group, The salmeterol multicenter asthma research trial: A comparison of usual
pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129,
15–26 (2006).
13. D. Cheung et al., Long-term effects of a long-acting beta 2-adrenoceptor agonist,
salmeterol, on airway hyperresponsiveness in patients with mild asthma. N. Engl.
J. Med. 327, 1198–1203 (1992).
14. J. Kraan, G. H. Koëter, T. W. vd Mark, H. J. Sluiter, K. de Vries, Changes in bronchial
hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients
with allergic asthma: A comparison between budesonide and terbutaline. J. Allergy
Clin. Immunol. 76, 628–636 (1985).
15. R. Beasley, N. Pearce, J. Crane, C. Burgess, Beta-agonists: What is the evidence that
their use increases the risk of asthma morbidity and mortality? J. Allergy Clin. Im-
munol. 104, S18–S30 (1999).
16. S. R. Salpeter, A. J. Wall, N. S. Buckley, Long-acting beta-agonists with and without
inhaled corticosteroids and catastrophic asthma events. Am. J. Med. 123, 322–8.e2
(2010).
17. W. H. Aisenberg et al., Defining an olfactory receptor function in airway smooth
muscle cells. Sci. Rep. 6, 38231 (2016).
18. S. S. An, S. B. Liggett, Taste and smell GPCRs in the lung: Evidence for a previously
unrecognized widespread chemosensory system. Cell. Signal. 41, 82–88 (2018).
19. D. A. Deshpande et al., Bitter taste receptors on airway smooth muscle bronchodilate
by localized calcium signaling and reverse obstruction. Nat. Med. 16, 1299–1304
(2010).
20. S. S. An, K. S. Robinett, D. A. Deshpande, W. C. Wang, S. B. Liggett, Reply to: Acti-
vation of BK channels may not be required for bitter tastant-induced bronchodila-
tion. Nat. Med. 18, 650–651 (2012).
21. S. S. An et al., TAS2R activation promotes airway smooth muscle relaxation despite
β(2)-adrenergic receptor tachyphylaxis. Am. J. Physiol. Lung Cell. Mol. Physiol. 303,
L304–L311 (2012).
22. D. A. Deshpande et al., Bronchodilator activity of bitter tastants in human tissue. Nat.
Med. 17, 776–778 (2011).
23. S. J. Lee, I. Depoortere, H. Hatt, Therapeutic potential of ectopic olfactory and taste
receptors. Nat. Rev. Drug Discov. 18, 116–138 (2019).
24. M. Parmentier et al., Expression of members of the putative olfactory receptor gene
family in mammalian germ cells. Nature 355, 453–455 (1992).
25. M. Spehr et al., Identification of a testicular odorant receptor mediating human
sperm chemotaxis. Science 299, 2054–2058 (2003).
26. C. Flegel et al., Characterization of the olfactory receptors expressed in human
spermatozoa. Front. Mol. Biosci. 2, 73 (2016).
27. L. Buck, R. Axel, A novel multigene family may encode odorant receptors: A molecular
basis for odor recognition. Cell 65, 175–187 (1991).
28. J. Bradley, J. Li, N. Davidson, H. A. Lester, K. Zinn, Heteromeric olfactory cyclic
nucleotide-gated channels: A subunit that confers increased sensitivity to cAMP. Proc.
Natl. Acad. Sci. U.S.A. 91, 8890–8894 (1994).
29. S. D. Munger, Olfaction: Noses within noses. Nature 459, 521–522 (2009).






















30. S. Katada, T. Hirokawa, Y. Oka, M. Suwa, K. Touhara, Structural basis for a broad but
selective ligand spectrum of a mouse olfactory receptor: Mapping the odorant-
binding site. J. Neurosci. 25, 1806–1815 (2005).
31. H. Kida et al., Vapor detection and discrimination with a panel of odorant receptors.
Nat. Commun. 9, 4556 (2018).
32. K. Schmiedeberg et al., Structural determinants of odorant recognition by the human
olfactory receptors OR1A1 and OR1A2. J. Struct. Biol. 159, 400–412 (2007).
33. M. D. Bhaskaran, B. N. Smith, Cannabinoid-mediated inhibition of recurrent excit-
atory circuitry in the dentate gyrus in a mouse model of temporal lobe epilepsy. PLoS
One 5, e10683 (2010).
34. K. Jiang et al., Geraniol alleviates LPS-induced acute lung injury in mice via inhibiting
inflammation and apoptosis. Oncotarget 8, 71038–71053 (2017).
35. A. Kozioł et al., An overview of the pharmacological properties and potential ap-
plications of natural monoterpenes. Mini Rev. Med. Chem. 14, 1156–1168 (2014).
36. N. Yadav, H. Chandra, Suppression of inflammatory and infection responses in lung
macrophages by eucalyptus oil and its constituent 1,8-cineole: Role of pattern rec-
ognition receptors TREM-1 and NLRP3, the MAP kinase regulator MKP-1, and NFκB.
PLoS One 12, e0188232 (2017).
37. S. J. Mundell, M. E. Olah, R. A. Panettieri, J. L. Benovic, R. B. Penn, Regulation of G
protein-coupled receptor-adenylyl cyclase responsiveness in human airway smooth
muscle by exogenous and autocrine adenosine. Am. J. Respir. Cell Mol. Biol. 24,
155–163 (2001).
38. G. Ortar et al., Effect of acyclic monoterpene alcohols and their derivatives on TRP
channels. Bioorg. Med. Chem. Lett. 24, 5507–5511 (2014).
39. M. J. Pérez de Vega, I. Gómez-Monterrey, A. Ferrer-Montiel, R. González-Muñiz,
Transient receptor potential melastatin 8 channel (TRPM8) modulation: Cool entry-
way for treating pain and cancer. J. Med. Chem. 59, 10006–10029 (2016).
40. S. C. Stotz, J. Vriens, D. Martyn, J. Clardy, D. E. Clapham, Citral sensing by transient
[corrected] receptor potential channels in dorsal root ganglion neurons. PLoS One 3,
e2082 (2008).
41. Y. Jiang et al., Molecular profiling of activated olfactory neurons identifies odorant
receptors for odors in vivo. Nat. Neurosci. 18, 1446–1454 (2015).
42. B. von der Weid et al., Large-scale transcriptional profiling of chemosensory neurons
identifies receptor-ligand pairs in vivo. Nat. Neurosci. 18, 1455–1463 (2015).
43. S. S. An, C. M. Hai, Mechanical signals and mechanosensitive modulation of intra-
cellular [Ca(2+)] in smooth muscle. Am. J. Physiol. Cell Physiol. 279, C1375–C1384
(2000).
44. A. P. Somlyo, A. V. Somlyo, Signal transduction and regulation in smooth muscle.
Nature 372, 231–236 (1994).
45. T. Pera, R. B. Penn, Bronchoprotection and bronchorelaxation in asthma: New targets,
and new ways to target the old ones. Pharmacol. Ther. 164, 82–96 (2016).
46. M. Schramm, G. Thomas, R. Towart, G. Franckowiak, Novel dihydropyridines with
positive inotropic action through activation of Ca2+ channels. Nature 303, 535–537
(1983).
47. D. Schild, D. Restrepo, Transduction mechanisms in vertebrate olfactory receptor cells.
Physiol. Rev. 78, 429–466 (1998).
48. K. Ma et al., Phosphate-induced ORAI1 expression and store-operated Ca2+ entry in
aortic smooth muscle cells. J. Mol. Med. (Berl.) 97, 1465–1475 (2019).
49. X. Cao et al., The ER/PM microdomain, PI(4,5)P2 and the regulation of STIM1-Orai1
channel function. Cell Calcium 58, 342–348 (2015).
50. A. Son, S. Park, D. M. Shin, S. Muallem, Orai1 and STIM1 in ER/PM junctions: Roles in
pancreatic cell function and dysfunction. Am. J. Physiol. Cell Physiol. 310, C414–C422
(2016).
51. R. C. Li et al., Ca2+-activated Cl current predominates in threshold response of mouse
olfactory receptor neurons. Proc. Natl. Acad. Sci. U.S.A. 115, 5570–5575 (2018).
52. A. Caputo et al., TMEM16A, a membrane protein associated with calcium-dependent
chloride channel activity. Science 322, 590–594 (2008).
53. B. C. Schroeder, T. Cheng, Y. N. Jan, L. Y. Jan, Expression cloning of TMEM16A as a
calcium-activated chloride channel subunit. Cell 134, 1019–1029 (2008).
54. Y. D. Yang et al., TMEM16A confers receptor-activated calcium-dependent chloride
conductance. Nature 455, 1210–1215 (2008).
55. F. Huang et al., Studies on expression and function of the TMEM16A calcium-
activated chloride channel. Proc. Natl. Acad. Sci. U.S.A. 106, 21413–21418 (2009).
56. G. Gallos et al., Functional expression of the TMEM16 family of calcium-activated
chloride channels in airway smooth muscle. Am. J. Physiol. Lung Cell. Mol. Physiol.
305, L625–L634 (2013).
57. U. Oh, J. Jung, Cellular functions of TMEM16/anoctamin. Pflugers Arch. 468, 443–453
(2016).
58. N. Pedemonte, L. J. Galietta, Structure and function of TMEM16 proteins (anocta-
mins). Physiol. Rev. 94, 419–459 (2014).
59. C. Flegel et al., RNA-seq analysis of human trigeminal and dorsal root ganglia with a
focus on chemoreceptors. PLoS One 10, e0128951 (2015).
60. J. Danielsson et al., Agonism of the TMEM16A calcium-activated chloride channel
modulates airway smooth muscle tone. Am. J. Physiol. Lung Cell. Mol. Physiol. 318,
L287–L295 (2020).
61. J. Danielsson et al., Antagonists of the TMEM16A calcium-activated chloride channel
modulate airway smooth muscle tone and intracellular calcium. Anesthesiology 123,
569–581 (2015).
62. T. Garzon-Muvdi et al., Regulation of brain tumor dispersal by NKCC1 through a novel
role in focal adhesion regulation. PLoS Biol. 10, e1001320 (2012).
63. R. Benedetto et al., Epithelial chloride transport by CFTR requires TMEM16A. Sci. Rep.
7, 12397 (2017).
64. G. R. Cutting, Cystic fibrosis genetics: From molecular understanding to clinical ap-
plication. Nat. Rev. Genet. 16, 45–56 (2015).
65. D. P. Cook et al., Cystic fibrosis transmembrane conductance regulator in sarcoplasmic
reticulum of airway smooth muscle. Implications for airway contractility. Am.
J. Respir. Crit. Care Med. 193, 417–426 (2016).
66. Z. Bozoky et al., Synergy of cAMP and calcium signaling pathways in CFTR regulation.
Proc. Natl. Acad. Sci. U.S.A. 114, E2086–E2095 (2017).
67. P. R. Cooper et al., TLR3 activation stimulates cytokine secretion without altering
agonist-induced human small airway contraction or relaxation. Am. J. Physiol. Lung
Cell. Mol. Physiol. 297, L530–L537 (2009).
68. C. J. Koziol-White et al., Inhibition of spleen tyrosine kinase attenuates IgE-mediated
airway contraction and mediator release in human precision cut lung slices. Br.
J. Pharmacol. 173, 3080–3087 (2016).
69. J. L. Pluznick et al., Olfactory receptor responding to gut microbiota-derived signals
plays a role in renin secretion and blood pressure regulation. Proc. Natl. Acad. Sci.
U.S.A. 110, 4410–4415 (2013).
70. B. D. Shepard, N. Natarajan, R. J. Protzko, O. W. Acres, J. L. Pluznick, A cleavable
N-terminal signal peptide promotes widespread olfactory receptor surface expression
in HEK293T cells. PLoS One 8, e68758 (2013).
71. B. Fabry et al., Scaling the microrheology of living cells. Phys. Rev. Lett. 87,
148102 (2001).
Huang et al. PNAS | November 10, 2020 | vol. 117 | no. 45 | 28495
PH
YS
IO
LO
G
Y
D
ow
nl
oa
de
d 
by
 g
ue
st
 o
n 
D
ec
em
be
r 
18
, 2
02
0 
